Apellis raises $60M in series E

Autoimmune company Apellis Pharmaceuticals Inc. (Crestwood, Ky.) raised $60 million in a series E round on Aug. 10 led by Sectoral Asset Management. New investors Sofinnova Ventures, Vivo Capital, F-Prime Capital Partners and funds advised by Clough Capital and venBio Select also participated, as did existing investors Morningside Ventures, Cormorant Asset Management, venBio Global Strategic Fund and Epidarex...